With a population of only 17 million, the Netherlands cannot be counted as one of the top five European pharma markets. Furthermore, an extremely high ratio of healthcare expenditure as a percentage of GDP has led the Dutch government to adopt a stance of avoiding any further increase, and the incumbent administration is now steadfast in its resolve to curb the blind reimbursement of innovative products.
Such a focus on cost-effectiveness has inevitably transformed this mid-size market into a particularly tricky country for innovator pharmaceutical companies.
Despite this uninviting context, the Netherlands Pharma Report paints a picture of a territory rivalling all in inventiveness to maintain its position as one of the best healthcare systems in the world — and to continue ensuring Dutch patients can benefit from the most recent treatments and care processes.
That means, first, that Dutch government and public authorities are leading the way to design a more sustainable and efficient healthcare system. Increasing transparency, empowering the patient, developing home care, modernizing hospital IT and fostering a greater collaboration at the EU level, are some of the vigorous initiatives recently championed by the Dutch government – and concretely supported by pharma and medtech companies.
Furthermore, in a country where collaboration holds supreme importance, the pharmaceutical industry is also compelled to take initiatives to continue reaching the Dutch market. In the Netherlands, local affiliates are thus transcending treatment quality by a concrete openness to partnership with regulators, while the industry is locally implementing experimental market access models.
This report for pharmaceutical executives also addresses the booming Dutch biotech scene, which truly propels the entire local value chain and strengthens the Netherlands’ innovative reputation.